Central nervous system specialist Neuraxpharm Arzneimittel GmbH, headquartered in Dusseldorf and Barcelona, announced 12 July that it is strengthening its position as a leading European specialty pharmaceutical company focused on the central nervous system by acquiring two product portfolios for CNS disorders, pain and vascular diseases from French pharma Sanofi. Neuraxpharm is active in 19 European counties, and the Sanofi products will bring it into more than 50 countries globally.
Deal Watch: Sanofi Offloads Established Products, Lilly Testing 3D-Printed Drugs
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.
